



IP SERVICES

Home IP Services PATENTSCOPE® Patent Search



Search result: 1 of 1

## (WO/1996/000581) PROCESS TO INHIBIT BINDING OF THE INTEGRIN ALPHA 4 BETA 1 TO VCAM-1 OR FIBRONECTIN

Biblio. Data	Description	Claims	National Phase	Notices	Documents
--------------	-------------	--------	----------------	---------	-----------

Latest bibliographic data on file with the International Bureau



**Pub. No.:** WO/1996/000581 **International Application No.:** PCT/US1995/008353  
**Publication Date:** 11.01.1996 **International Filing Date:** 27.06.1995  
**Chapter 2 Demand Filed:** 22.01.1996

**IPC:** C07K 14/78 (2006.01), A61K 38/00 (2006.01)

**Applicants:** TEXAS BIOTECHNOLOGY CORPORATION [US/US]; Suite 1920, 7000 Fannin Street, Houston, TX 77030 (US) (All Except US).  
 KOGAN, Timothy, P. [US/US]; (US) (US Only).  
 REN, Kaijun [CN/US]; (US) (US Only).  
 VANDERSLICE, Peter [US/US]; (US) (US Only).  
 BECK, Pamela, J. [US/US]; (US) (US Only).

**Inventors:** KOGAN, Timothy, P.; (US).  
 REN, Kaijun; (US).  
 VANDERSLICE, Peter; (US).  
 BECK, Pamela, J.; (US).

**Agent:** KATZ, Martin, L.; Dressler, Goldsmith, Shore & Milnamow, Ltd., Suite 4700, Two Prudential Plaza, Chicago, IL 60601 (US).

**Priority Data:** 08/268,192 29.06.1994 US

**Title:** PROCESS TO INHIBIT BINDING OF THE INTEGRIN ALPHA 4 BETA 1 TO VCAM-1 OR FIBRONECTIN

**Abstract:** The present invention is directed to an isolated and purified cyclic peptide of from 5 to about 13 residues modeled after a portion of the CS1 peptide. A peptide of this invention preferably has the amino acid residue sequence of SEQ ID NO:2-14 or 16-42. The present invention is further directed to a process of selectively inhibiting the binding of  $\text{Ig(a)}_4\text{?Ig(b)}_4\text{?}$  integrin to a protein such as VCAM-1, fibronectin or invasins comprising exposing a cell that expresses  $\text{Ig(a)}_4\text{?Ig(b)}_4\text{?}$  integrin to that protein in the presence of an effective inhibiting amount of such a peptide. The present invention is still further directed to a pharmaceutical composition comprising a physiologically acceptable carrier and a cyclic peptide of the invention.

**Designated States:** AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN.  
 African Regional Intellectual Property Org. (ARIPO) (KE, MW, SD, SZ, UG)  
 European Patent Office (EPO) (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)  
 African Intellectual Property Organization (OAPI) (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

**Publication Language:** English (EN)  
**Filing Language:** English (EN)

